# A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

> **NCT05406401** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 60 (estimated)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse (DLBCL)

## Interventions

- **BIOLOGICAL:** Zilovertamab Vedotin
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Rituximab Biosimilar
- **DRUG:** Prednisone
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT05406401
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-14
- **Primary completion:** 2029-04-26
- **Final completion:** 2029-04-26
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05406401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05406401, "A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05406401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*